The Scoop
German medtech startup Sedivention raised €2.9M seed funding led by bmp Ventures and IBG funds. They're developing a one-time, minimally invasive obesity therapy using cryoablation.
The Context
Sedivention's therapy targets the vagus nerve to reduce hunger signals without surgery or long-term medication, addressing a global obesity crisis. Current treatments are often invasive or costly. This funding allows Sedivention to advance product development and initiate human clinical trials, potentially disrupting the market. Obesity tech is drawing increasing investor interest.